Pfizer, Lilly and Bayer fined for price-fixing in Switzerland

he Swiss branches of Pfizer Inc., Eli Lilly & Co. and Bayer AG were fined a total of $5.7 million by competition regulators on Dec. 1 for alleged price-fixing of drugs for erectile dysfunction.

Register for free to listen to this article
Listen with Speechify
0:00
5:00
BERN, Switzerland—The Swiss branches of Pfizer Inc., EliLilly & Co. and Bayer AG were fined a total of $5.7 million by competitionregulators on Dec. 1 for alleged price-fixing of drugs for erectiledysfunction. The Swiss Competition Commission contends that the prices forViagra (sildenafil), Cialis (tadalafil) and Levitra (vardenafil) were fixed viapublic price recommendations. The commission didn't say how much each companywas fined, and declined to provide the information. The commission concluded inFebruary, after a lengthy investigation that began in June 2006, that the firmsmade "inadmissible vertical competition agreements" by maintaining arecommended public selling price for the drugs. The three companies rejectedthe allegations.
  
 
  
 
  
  
 


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue